Trial · NCT00705016
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) Time: Investigator Read | Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 6.4 | 95% Confidence Interval 5.4 to 8.7 | months | |
| Progression-free Survival (PFS) Time: Investigator Read | Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 5.6 | 95% Confidence Interval 4.0 to 6.1 | months | |
| Progression-free Survival (PFS) Time: Investigator Read | Cetuximab+5-FU+Cisplatin | 5.7 | 95% Confidence Interval 4.2 to 9.5 | months | |
| Overall Survival (OS) Time | Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 12.4 | 95% Confidence Interval 9.4 to 14.5 | months | |
| Overall Survival (OS) Time | Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 10.6 | 95% Confidence Interval 9.0 to 14.8 | months | |
| Overall Survival (OS) Time | Cetuximab+5-FU+Cisplatin | 11.6 | 95% Confidence Interval 7.1 to 16.4 | months | |
| Best Overall Response (BOR) Rate | Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 46.8 | 95% Confidence Interval 34.0 to 59.9 | percentage of participants | |
| Best Overall Response (BOR) Rate | Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 26.7 | 95% Confidence Interval 16.1 to 39.7 | percentage of participants | |
| Best Overall Response (BOR) Rate | Cetuximab+5-FU+Cisplatin | 35.5 | 95% Confidence Interval 23.7 to 48.7 | percentage of participants | |
| Disease Control Rate | Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 85.5 | 95% Confidence Interval 74.2 to 93.1 | percentage of participants | |
| Disease Control Rate | Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 73.3 | 95% Confidence Interval 60.3 to 83.9 | percentage of participants | |
| Disease Control Rate | Cetuximab+5-FU+Cisplatin | 80.6 | 95% Confidence Interval 68.6 to 89.6 | percentage of participants | |
| Time to Treatment Failure (TTF) | Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 5.6 | 95% Confidence Interval 4.2 to 6.9 | months | |
| Time to Treatment Failure (TTF) | Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 4.5 | 95% Confidence Interval 2.9 to 5.6 | months | |
| Time to Treatment Failure (TTF) | Cetuximab+5-FU+Cisplatin | 4.3 | 95% Confidence Interval 3.8 to 7.3 | months | |
| Duration of Response | Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 5.8 | 95% Confidence Interval 4.5 to 7.5 | months | |
| Duration of Response | Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 4.1 | 95% Confidence Interval 3.1 to 4.4 | months | |
| Duration of Response | Cetuximab+5-FU+Cisplatin | 6.4 | 95% Confidence Interval 4.2 to 9.7 | months | |
| Safety - Number of Participants Experiencing Any Adverse Event | Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 61 | participants | ||
| Safety - Number of Participants Experiencing Any Adverse Event | Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 59 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00705016/results